SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete
about
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disordersEndocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetesTackling obesity: new therapeutic agents for assisted weight loss.Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes.Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controlsA novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodentsMarijuana-based drugs: innovative therapeutics or designer drugs of abuse?Rimonabant: From RIO to Ban.The psychiatric side-effects of rimonabant.The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiationThe endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complicationsControlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.Modulating the endocannabinoid system in human health and disease--successes and failuresVariants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart diseaseDevelopmental role for endocannabinoid signaling in regulating glucose metabolism and growth.Strategies for preventing type 2 diabetes: an update for clinicians.The future of endocannabinoid-oriented clinical research after CB1 antagonists.The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant.The emerging role of the endocannabinoid system in cardiovascular disease.Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.Renal effects of chronic pharmacological manipulation of CB2 receptors in rats with diet-induced obesity.Neuropsychiatric adverse effects of centrally acting antiobesity drugs.Anti-obesity drugs: a review about their effects and their safety.CB1 receptor antagonists: new discoveries leading to new perspectives.Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology.The unrelenting fall of the pharmacological treatment of obesity.Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes.Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions.Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.Choice of estimand and analysis methods in diabetes trials with rescue medication.American College of Endocrinology Pre-Diabetes Consensus Conference: part two.Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight.Many Flavors of Model-Based Meta-Analysis: Part II - Modeling Summary Level Longitudinal Responses.
P2860
Q24658031-2BD5F3CA-51B4-4FAB-9132-F12933BBA364Q28078897-75F9238F-9568-4A73-A898-03FFC0CF130EQ30401145-A6902D8D-E45D-4675-AA6A-8EB8B789D2BCQ30473707-33DC6836-6509-4759-B20E-073AE1A3EF75Q33509626-E8B69107-D567-4B4F-9C56-81474F381074Q33731729-747E27C3-D8F8-4F10-B48E-ABD3B5C9125BQ34022349-93E90DD5-3C08-4672-90F3-F3D986E401FCQ34140803-8DC72098-97F0-4584-8D74-95CA8114C62BQ34173626-912D38DC-1AA5-4DC6-989D-8A36928AA1E9Q34202105-1E9A064E-3F56-4066-94C5-6F8DD7CB6BFAQ34990771-41F9A720-35FE-41B5-A904-335FA17C39E6Q35193287-F7A3C060-F354-43CD-9976-9FBA48FA5CD3Q35658286-AC311568-9C85-43CD-934E-D4162EE39CE2Q35951992-A9EEF5F5-825A-4CED-BC05-93E66E05D607Q36373581-BB1C5278-1AC9-4756-ACBB-8D57BEA95F12Q36933683-DBB319C7-4A33-4C6C-AA2E-9A3C1D2C2F97Q36940105-76B2A9E1-C987-4AC2-9B51-DFFF4E07CE61Q37015008-46FF3E3F-29EB-40C2-A08A-EED05C1027E5Q37117608-C09464C7-2D5D-4AB0-A2B1-9CED670ECF4FQ37226111-3531762A-95F8-4C63-84BF-0180953BEBA1Q37405671-673E50C7-4197-46F2-BD88-E244752C03B7Q37439386-1C38664E-AFAC-4EFB-B838-C85DAD474F55Q37581457-EA2E6CF4-8C0A-4D6F-A475-C56142EAF4EDQ37681996-7A88F3DF-DEEE-4E41-91A8-FB37FFBE10BFQ37939362-2AAF9E00-C5C9-444A-BCD1-291B05DB9607Q37996099-43CC1B44-8DA7-4F72-A6FE-0EB80EF41E15Q37998561-0E3BB0D1-6ECF-4181-9FA5-1EB79E7C268DQ38068594-75F836AC-6BDA-4A23-8F79-9EDAC166F5B0Q38107134-1EFE0C54-07D4-45CF-B16B-3DE61BC1AD18Q38729150-941D792A-564D-479F-A906-5284D2196389Q38924783-821AEF15-31CE-4C89-8155-C9C58489B28DQ39234563-5D5A918D-637B-472B-ADC6-CF061C2AD22EQ40576360-7A352818-3290-497D-9F97-61D46F940A8EQ42711225-0E2807AA-58FC-4C8E-BD93-BA87FC71674BQ43145354-B95E0C59-AF30-4BA1-BDA2-9E5D305467C8Q45288843-FF640F4D-F99A-4C04-A742-5220BDBA4748Q47330379-F3CAA194-C9A6-42EE-8D25-0565DBA83DCCQ54942333-CF69F5B6-FA89-44F7-9ED4-BD3FB652B9BB
P2860
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
SERENADE: the Study Evaluating ...... e in drug-naive type 2 diabete
@en
type
label
SERENADE: the Study Evaluating ...... e in drug-naive type 2 diabete
@en
prefLabel
SERENADE: the Study Evaluating ...... e in drug-naive type 2 diabete
@en
P2093
P2860
P356
P1433
P1476
SERENADE: the Study Evaluating ...... e in drug-naive type 2 diabete
@en
P2093
Ali Iranmanesh
Priscilla Hollander
SERENADE Study Group
Soazig Chevalier
P2860
P304
P356
10.2337/DC08-0386
P407
P577
2008-08-04T00:00:00Z